Table of contents
- Trial overview
- Who was studied
- Treatments tested
- Study phases and goals
- Endpoints measured
- What the results mean for patients
Trial overview
The available clinical trial data describe one interventional study of Ale.c04 in people with recurrent or metastatic head and neck squamous cell carcinoma.[1] The study was completed and enrolled 160 participants.[1]
This trial was designed as a first-in-human study, meaning it was the first time the treatment was tested in people for this condition.[1]
Who was studied
The trial focused on adults with recurrent or metastatic head and neck squamous cell carcinoma, which is a cancer that has come back after treatment or has spread to other parts of the body.[1]
Because the trial targeted this specific cancer type, the results are meant for patients with this disease rather than for all cancer patients.[1]
Treatments tested
The study tested Ale.c04 as monotherapy, which means it was given alone, and also in combination with pembrolizumab.[1] Pembrolizumab was listed in the trial as KEYTRUDA concentrate for solution for infusion.[1]
Both treatments were given by intravenous infusion, meaning through a vein.[1]
Study phases and goals
The trial was a Phase 1/2 study.[1] Phase 1 usually focuses on safety, tolerability, and dose finding, while Phase 2 looks more closely at whether the treatment may help the cancer.[1]
The brief summary listed three main goals: to evaluate safety and tolerability of Ale.c04 alone and with pembrolizumab, to establish the recommended Phase 2 dose for the combination, and to compare anti-tumor efficacy of the combination versus pembrolizumab alone.[1]
The study therefore had both a dose-finding part and a comparison part, which is common in early cancer research when a new treatment is being developed.[1]
Endpoints measured
The main outcomes included dose-limiting toxicities, which are side effects serious enough to limit how much treatment can be given.[1] The study also measured the incidence and severity of adverse events and serious adverse events, which are unwanted medical problems during treatment.[1]
Other safety checks included changes in laboratory values, vital signs, and ECGs, which are tests used to monitor the body, blood tests, heart rhythm, and overall treatment tolerance.[1] The trial also tracked dose interruptions and dose intensity, meaning whether treatment had to be paused and how much treatment was actually delivered.[1]
For effectiveness, the study compared progression-free survival by RECIST 1.1 using blinded independent central review.[1] Progression-free survival is the time during which the cancer does not get worse, and RECIST 1.1 is a standard way to measure tumor change on scans.[1] Blinded independent central review means scan results are checked by independent experts who do not know which treatment was given.[1]
The study also planned subgroup analyses for CLDN1 and PD-L1, which means the researchers looked at whether results differed in certain biological groups.[1]
What the results mean for patients
From the trial design, Ale.c04 was being explored as a possible new option for a difficult-to-treat cancer setting.[1] The study was not only checking whether the treatment could be given safely, but also whether adding it to pembrolizumab might improve cancer control compared with pembrolizumab alone.[1]
Because the study was completed, the trial data now provide information on how the research was structured and what outcomes were measured in this patient group.[1]
